trial

R33: Levetiracetam in Early Psychosis

NCTId NCT04317807
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 65 (actual)
Sponsored by NYU Langone Health
Primary completion 2025-04-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
65 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-08-27
Primary completion
2025-04-01
Eligibility
ALL · 16 Years · 40 Years

Interventions & indications

Drugs
Levetiracetam Pill

Sponsors

NYU Langone HealthLead Sponsor

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
R33: Levetiracetam in Early Psychosis — primary completion2025-04-01

Facts & assertions

4 sourced
Enrollment
65
Phase
PHASE2
Primary Completion Date
2025-04-01
Status
COMPLETED
relationships
The graph out of here
drug
Levetiracetam Pill
drug
lead_sponsor
NYU Langone Health
company
indication
Early Psychosis
indication
Psychotic Disorders
indication
investigator
Donald C. Goff, MD
person